Oct 27 (Reuters) - Intellia Therapeutics ( NTLA ) said
on Monday it has temporarily stopped dosing and screening
patients in two late-stage studies of its one-time gene-editing
treatment for a heart condition after a patient experienced a
serious liver problem.